Biovie Inc. · NASDAQ:BIVI
Biovie — Corporate Update (April 2021)
22 slides from Biovie's corporate update, Apr 27, 2021
Slide 1: Investor & Analyst Conference Call
biovie Investor & Analyst Conference Call Corporate Presentation April 27, 2027
Slide 2: Forward-looking Statements
Forward-looking Statements ‘This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie's actual results and experience to differ materi
Slide 3: Agenda
| Agenda Appointment of Cuong Do as President & CEO Transaction + Veteran biotech and pharma industry leader + Upfront consideration mostly based on newly issued shares. Ad payments upon meeting significant milestones I) + Founder of Callidus Biopharma, Lysodel Therapeutics es and Mé6P Therapeutics
Slide 4: A New Vision for BioVie
A New Vision for BioVie Biopharma company focused on multiple therapeutic areas with unmet medical needs + Advanced Liver Disease + Neurodegenerative + Neurological * Several Oncologic Indications
Slide 5: Compelling Asset Portfolio
Compelling Asset Portfolio BIV201 + Phase 2b trial in refractory ascites underway. Agreement with FDA on pivotal Phase 3 design + Continuous infusion terlipressin offers potential for safe therapy at home NE3107 + Pivotal Phase 3 stage asset + First-in-class small molecule inhibitor of inflammation
Slide 6: Opportunity with BIV201
| Opportunity with BIV201 $670M ‘Addressable US 20,000 |0 Number of FDA- Phase 2 Pivotal Phase 3 in 2022 ascites market size"; | US patients approved drugs | Phase 2b studyis Projected BIV201 US | targeted for to specifically underway; FDA Fast peak sales of $450M | BIV201 therapy | treat ascites, T
Slide 7: About NeurMedix Assets
About NeurMedix Assets Years of research on inhibiting the pathological inflammatory cascade and insulin resistance in the brain Attractive assets/IP with remarkably broad applicability across diseases Rare Phase 3 asset with multiple follow-ons in other indications
Slide 8: NeurMedix Transaction
| NeurMedix Transaction Investor Friendly Terms E3107 and MeotO7 are les OFS Research vvertse L2G + First-in-lass potent & safe Clarence Ahlem,COO + Modest upfront payment Inhibition ofthe nathelcelcal Chris Reading, PhD. CSO. + Milestones contingent on inflammatory cascade it ¢ Lacugonsue te bostv
Slide 9: Significance of Inflammation
Significance of Inflammation + Alzheimer's Disease + Multiple Myeloma + Parkinson's + Castrate-resistant Prostate n*nsulii celts! + Other inflammation-driven cancers + Other inflammation-driven suchas diseases such as + Breast + Rheumatoid arthritis + Colon + Osteoporosis * Gastric * Cystic fibrosis
Slide 10: Disrupting Biological Pathways
Disrupting Biological Pathways * Protein complexes are 3-D structures + Each complex could have multiple roles in multiple biological pathways + Challengeis to selectively change the conformation to: + Interrupt interactions in the deleterious pathway + While not disturbing. Precision critical for e
Slide 11: NE3107: A Differentiated Molecule
NE3107: A Differentiated Molecule + First-in-class molecule with desirable characteristics + Small molecule + Crosses blood-brain barrier + Excellent safety profile demonstrated in pre-clinical and clinical trials * Blocks neuroinflammation and insulin-resistance at the right time/place in pathologi
Slide 12: Extracellular Signal-Related Kinase
Extracellular Signal-Related Kinase (ERK) Homeostatic Inflammatory Pathways Pathways via Ras/Raf/Mek via NFkB Critical player for both homeostasis and inflammation (and inflammation-induced insulin resistance)
Slide 13: NE3107 is Highly Selective
NE3107 is Highly Selective + Blocks only inflammatory phosphorylation of ERK by MEK + Breaks TNFa reactivation cycle MEK + Inhibits inflammation- induced insulin resistance + Does not appear to affect x ERK phosphorvltion by + Ras/Raf/MEK + No effects on homeostasis
Slide 14: NE3107 Applicability
| NE3107 Applicability BERD IESE « Reduces inflammation ad insulin resistance implicated in Alzheimer’s + Reduces inflammation, insulin resistance and parkinsonism in low dopamine environments A libdeliaaiadl «TNE reduction reduces levadopainduced dyskinesia + MM cells secrete cytokines (eg, TNFa) a
Slide 15: Others
Others | NE3107 vs. 1 Broseratntanmatory avy IN 017 decrees fret madtedy TR among oer cts By during UR AT S097 sees naan vatheNPS pathy ty comsteam nthe sty Satie cin Rawat outst e
Slide 16: Pipeline
Pipeline ——_“ << § Pacis! => Mutile or: Ey <== : * Drugdrug interaction study with levodopa required to proceed to Phase 2
Slide 17: Deal Overview
Deal Overview Upfront Considerations Contingent Milestones * Atclosing + Payable in shares; capped at 90% ownership + 8:361,308 newiy issued shares + $350 million upon hitting endpoints in pivotal trials + Approximately $3 0milionin cash + $700 million upon FDA acceptance of NDA filing + Additional
Slide 18: Catalysts & Timelines (US)
| Catalysts & Timelines (US) | Alzheimers
Slide 19: Next Steps
Next Steps + Advance clinical programs + Expand leadership to pursue opportunities + Finalize development plans
Slide 20: Recap
Recap + BIV201 provides foundation + NeurMedix assets allow BioVie to address some of the greatest unmet needs in medicine * Delivers advances for patients * Generates returns for shareholders * Diversifies BioVie's portfolio with unique assets transforming BioVie into a broad-based biopharma compan
Slide 21: R&D Day
| R&D Day + Wednesday, May 19' at 12:00 - 2:00 p.m. EDT * Opportunity to delve deeper into our R&D programs and plans
Slide 22: Slide 22